Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORDUS: Umbilical Cord Blood vs Personalized Treatment in ASD
NCT04007224Phase 1Completed
- Sponsor
- Fundatia Bio-Forum
- Start
- Jan 2019
- Primary completion
- Jun 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of autologous umbilical cord blood reinfusion in Autism Spectrum Disorder (ASD) (2 arms), sponsored by Fundatia Bio-Forum. Primary endpoints: Improvement in behaviour, interaction with family and peers at 2 months, Improvement in behavior and social interaction at 2 months and 1 more. Started Jan 2019; status: completed.
02
Drugs
autologous umbilical cord blood reinfusion
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT04007224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04007224.